The discovery of "Riyadhensis" reinforces the potential of genomic tests in innovating promising diagnostic and therapeutic methods, as well as deepening the understanding of bacterial resistance mechanisms, particularly in sensitive environments like intensive care units (ICU) and among patients with compromised immune systems. This represents substantial progress in combating antibiotic resistance, developing pharmaceuticals, and preventing the spread of diseases.

This newly identified bacteria was discovered amid an in-depth investigation into a suspected outbreak in the ICU of KFSH&RC in 2019, highlighting challenges previously unrecognized by the global scientific and medical communities in pinpointing and countering new bacterial strains. Initially thought to be a variant of Pseudomonas aeruginosa, a disease-causing bacterium known for its resistance to antibiotics, subsequent WGS analysis revealed it did not share the common characteristics of the Pseudomonas genus. Instead, Riyadhensis was found to belong to the Stenotrophomonas family, with a unique genetic composition and morphological traits, unlike any other scientifically recognized members.

Dr. Ahmad Al Qahtani, Head of the Infectious Disease and Immunity Department at The research center of KFSH&RC stated: "Traditional bacterial identification methods may lead to misidentification, in contrast, WGS analysis offers a precise and targeted approach that ensures accurate identification and provides detailed insights into resistance mechanisms, proving its significance in disease outbreak investigations and patient care improvements."

Dr. Reem Almaghrabi, Head of Transplant Infectious Diseases at the Organ Transplant Centre of Excellence at KFSH&RC highlighted the discovery's importance in advocating for continuous monitoring and the use of advanced technologies like WGS in developing faster and more accurate diagnostic methods. Furthermore, this approach lays the groundwork for scientific collaboration at all levels, enhancing global efforts to combat antibiotic resistance.

Understanding the nuances of new bacterial species, particularly their antibiotic resistance, is crucial in modern healthcare and serves as the primary means of combating bacterial infections. As these bacteria continuously evolve their resistance, they pose a significant and ongoing threat to human health.

It is noteworthy that KFSH&RC has been ranked first in the Middle East and Africa, and 20th globally, in the list of the top 250 healthcare institutions worldwide for the second consecutive year, according to the 2024 Brand Finance rankings. Additionally in the same year, it was ranked among the world's best hospitals by the prestigious Newsweek magazine.

King Faisal Specialist Hospital & Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced hub for medical research and education. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating the standards of healthcare worldwide.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2024, "Brand Finance" ranked King Faisal Specialist Hospital & Research Centre as the top Academic Medical Centre in the Middle East and Africa, and among the top 20 globally. Additionally, in 2024, it was recognized as one of the World's Best Hospitals by Newsweek magazine, and ranked # 1 in KSA.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.